

Elena M Seminari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/118168/publications.pdf>

Version: 2024-02-01

89
papers

2,546
citations

201674

27
h-index

223800

46
g-index

93
all docs

93
docs citations

93
times ranked

4944
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. <i>Journal of Medical Virology</i> , 2020, 92, 1724-1727.	5.0	205
2	Low risk of SARS-CoV-2 transmission by fomites in real-life conditions. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e112.	9.1	138
3	Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1094.e1-1094.e5.	6.0	121
4	Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. <i>Eurosurveillance</i> , 2020, 25, .	7.0	119
5	Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. <i>Atherosclerosis</i> , 2002, 162, 433-438.	0.8	114
6	Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. <i>Haematologica</i> , 2020, 105, 2834-2840.	3.5	114
7	The Incidence and Spectrum of AIDS-Defining Illnesses in Persons Treated with Antiretroviral Drugs. <i>Clinical Infectious Diseases</i> , 1998, 27, 1379-1385.	5.8	102
8	SARS Cov-2 infection in a renal-transplanted patient: A case report. <i>American Journal of Transplantation</i> , 2020, 20, 1882-1884.	4.7	76
9	Structured treatment interruptions to control HIV-1 infection. <i>Lancet</i> , The, 2000, 355, 287-288.	13.7	72
10	A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. <i>Clinical Microbiology and Infection</i> , 2018, 24, 546.e1-546.e8.	6.0	67
11	EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. <i>International Journal of Infectious Diseases</i> , 2021, 104, 315-319.	3.3	66
12	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1886-1896.	3.0	56
13	Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. <i>HIV Medicine</i> , 2005, 6, 145-150.	2.2	54
14	Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 712-715.	2.4	53
15	The obesity paradox: Analysis from the SMAAtteo COvid-19 REgistry (SMACORE) cohort. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1920-1925.	2.6	53
16	Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. <i>Journal of Hospital Infection</i> , 2020, 105, 474-476.	2.9	51
17	Emergency Department and Out-of-Hospital Emergency System (112-AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre. <i>Internal and Emergency Medicine</i> , 2020, 15, 825-833.	2.0	50
18	Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy. <i>Microorganisms</i> , 2020, 8, 977.	3.6	41

#	ARTICLE	IF	CITATIONS
19	Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol. <i>Internal and Emergency Medicine</i> , 2020, 15, 819-824.	2.0	41
20	Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia. <i>Aids</i> , 2000, 14, 109-116.	2.2	38
21	Granule-dependent mechanisms of lysis are defective in CD8 T cells of HIV-infected, antiretroviral therapy-treated individuals. <i>Aids</i> , 2004, 18, 859-869.	2.2	36
22	Etravirine for the treatment of HIV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 427-433.	4.4	34
23	Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy. <i>Internal and Emergency Medicine</i> , 2020, 15, 1457-1465.	2.0	32
24	Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre. <i>Journal of Hospital Infection</i> , 2020, 105, 477-479.	2.9	31
25	High-Performance Liquid Chromatography Method for Analyzing the Antiretroviral Agent Efavirenz in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 346.	2.0	31
26	Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses. <i>HIV Clinical Trials</i> , 2002, 3, 115-124.	2.0	30
27	Adoptive Transfer of JC Virus-Specific T Lymphocytes for the Treatment of Progressive Multifocal Leukoencephalopathy. <i>Annals of Neurology</i> , 2021, 89, 769-779.	5.3	30
28	Safety, Tolerability, and Preliminary Efficacy of 48 Weeks of Etravirine Therapy in a Phase IIb Dose-Ranging Study Involving Treatment-Experienced Patients with HIV-1 Infection. <i>Clinical Infectious Diseases</i> , 2008, 47, 969-978.	5.8	29
29	Extended Infusion of Î²-Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1731-1739.	5.8	29
30	Hydroxyurea and Didanosine Long-Term Treatment Prevents HIV Breakthrough and Normalizes Immune Parameters. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1333-1338.	1.1	27
31	Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response. <i>Journal of Clinical Virology</i> , 2003, 26, 95-100.	3.1	23
32	Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 790-792.	3.0	23
33	Prevalence and epidemiological correlates and treatment outcome of HCV infection in an Italian prison setting. <i>BMC Public Health</i> , 2013, 13, 981.	2.9	23
34	High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. <i>Aids</i> , 1999, 13, 870.	2.2	22
35	Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAteo COvid19 REgistry (SMACORE). <i>Scientific Reports</i> , 2021, 11, 1137.	3.3	22
36	Efavirenz, Nelfinavir, and Stavudine Rescue Combination Therapy in HIV-1-Positive Patients Heavily Pretreated With Nucleoside Analogues and Protease Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 22, 453.	2.1	21

#	ARTICLE	IF	CITATIONS
37	Sex differences in nevirapine disposition in HIV-infected patients. <i>Aids</i> , 2003, 17, 2399-2400.	2.2	21
38	Worldwide clinical practices in perioperative antibiotic therapy for lung transplantation. <i>BMC Pulmonary Medicine</i> , 2020, 20, 109.	2.0	20
39	Hepatitis C Infection Influence on Immune Recovery in HIV-Positive Patients on Successful HAART: The Role of Genotype 3. <i>Current HIV Research</i> , 2010, 8, 186-193.	0.5	19
40	The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. <i>Journal of Medical Virology</i> , 2014, 86, 1648-1655.	5.0	19
41	Efavirenz, Nelfinavir, and Stavudine Rescue Combination Therapy in HIV-1 Positive Patients Heavily Pretreated With Nucleoside Analogues and Protease Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 22, 453.	2.1	18
42	Epidemiological characteristics of bloodstream infections in patients with different degrees of liver disease. <i>Infection</i> , 2015, 43, 561-567.	4.7	17
43	Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia. <i>American Journal of Transplantation</i> , 2020, 20, 1629-1641.	4.7	17
44	Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naïve chronically HIV-infected patients. <i>Aids</i> , 2002, 16, 1767-1773.	2.2	16
45	Predicting the magnitude of short-term CD4 ⁺ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 165-175.	1.0	16
46	Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 831-836.	3.0	15
47	Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 45, 343-347.	3.0	13
48	Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV hepatitis C virus co-infection. <i>Aids</i> , 2004, 18, 123-127.	2.2	13
49	Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients. <i>Aids</i> , 2003, 17, 2669-2671.	2.2	12
50	Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 545-549.	1.9	12
51	Post-exposure rate of tuberculosis infection among health care workers measured with tuberculin skin test conversion after unprotected exposure to patients with pulmonary tuberculosis: 6-year experience in an Italian teaching hospital. <i>BMC Infectious Diseases</i> , 2014, 14, 324.	2.9	11
52	Prosthetic Joint Infection from Carbapenemase-Resistant <i>Klebsiella pneumoniae</i> Successfully Treated with Ceftazidime-Avibactam. <i>Case Reports in Infectious Diseases</i> , 2018, 2018, 1-5.	0.5	11
53	QTc Interval and Mortality in a Population of SARS-2-CoV Infected Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008890.	4.8	11
54	Efficacy of β -lactam/ β -lactamase inhibitors to treat extended-spectrum β -lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-ESOT Project). <i>Transplant Infectious Disease</i> , 2021, 23, e13520.	1.7	10

#	ARTICLE	IF	CITATIONS
55	Robust and Persistent B- and T-Cell Responses after COVID-19 in Immunocompetent and Solid Organ Transplant Recipient Patients. <i>Viruses</i> , 2021, 13, 2261.	3.3	10
56	Modulation of Human Immunodeficiency Virus (HIV)-Specific Immune Response by Using Efavirenz, Nelfinavir, and Stavudine in a Rescue Therapy Regimen for HIV-Infected, Drug-Experienced Patients. <i>Vaccine Journal</i> , 2002, 9, 1114-1118.	3.1	9
57	Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant. <i>Microorganisms</i> , 2021, 9, 2622.	3.6	9
58	CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis. <i>AIDS Reviews</i> , 2008, 10, 236-44.	1.0	9
59	Changes in Darunavir/r Resistance Score After Previous Failure to Tipranavir/r in HIV-1-Infected Multidrug-Resistant Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 192-195.	2.1	8
60	Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1443-1446.	6.0	8
61	Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy. <i>Internal and Emergency Medicine</i> , 2021, 16, 1141-1152.	2.0	8
62	Nelfinavir Suspension Obtained from Nelfinavir Tablets Has Equivalent Pharmacokinetic Profile. <i>Journal of Chemotherapy</i> , 2001, 13, 569-574.	1.5	7
63	Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients. <i>Aids</i> , 2004, 18, 2205-2208.	2.2	7
64	Running out of bullets: The challenging management of acute hepatitis and SARS-CoV-2 from the SMatteo Covid19 Registry (SMACORE). <i>Liver International</i> , 2020, 40, 2655-2659.	3.9	7
65	Comparison of Costs of Strategies for Measuring Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma by Using Amplicor and Ultra Direct Assays. <i>Journal of Clinical Microbiology</i> , 1998, 36, 3369-3371.	3.9	7
66	Infective endocarditis in patients with hepatic diseases. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 279-284.	2.9	6
67	The role of qSOFA compared to other prognostic scores in septic patients upon admission to the emergency department. <i>European Journal of Internal Medicine</i> , 2018, 53, e11-e13.	2.2	6
68	What prompts clinicians to start antibiotic treatment in COVID-19 patients? An Italian web survey helps us to understand where the doubts lie. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 26, 74-76.	2.2	6
69	Colitis in an elderly immunocompetent patient. <i>Journal of Clinical Virology</i> , 2012, 55, 187-190.	3.1	5
70	Tuberculosis-induced haemophagocytic syndrome in a patient on haemodialysis treated with anti-thymocyte globulin [Correspondence]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 248-249.	1.2	5
71	Evaluation of a model to improve collection of blood cultures in patients with sepsis in the emergency room. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 241-246.	2.9	5
72	Outbreak of measles genotype H1 in Northern Italy originated from a case imported from Southeast Asia, 2017. <i>Clinical Microbiology and Infection</i> , 2019, 25, 526-528.	6.0	5

#	ARTICLE	IF	CITATIONS
73	Redistribution of Human Immunodeficiency Virus Type 1 Variants Resistant to Protease Inhibitors after a Protease Inhibitor-Sparing Regimen. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 545-554.	1.1	4
74	Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: A pilot randomised trial. <i>Journal of Clinical Virology</i> , 2010, 47, 253-257.	3.1	4
75	Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing COVID19 epidemics in Lombardy. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1569-1571.	6.0	4
76	Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 72-74.	2.6	4
77	Haemostatic Activation in HIV Infected Patients Treated with Different Antiretroviral Regimens. <i>Current HIV Research</i> , 2008, 6, 70-76.	0.5	3
78	A Case Report of Disseminated Histoplasmosis in AIDS Diagnosed Through Peripheral Blood Smear. <i>Current HIV Research</i> , 2021, 19, 457-459.	0.5	3
79	QTc prolongation and mortality in SARS-2-CoV-infected patients treated with azithromycin and hydroxychloroquine. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, e21-e23.	1.5	3
80	Minimally invasive procedure for removal of infected ventriculoatrial shunts. <i>Acta Neurochirurgica</i> , 2021, 163, 455-462.	1.7	3
81	Epidemiology of Mycobacterium tuberculosis infection in Pavia province, Lombardy, Northern Italy, 1998-2013. <i>New Microbiologica</i> , 2016, 39, 264-268.	0.1	3
82	Differences in implementation of HIV/AIDS clinical research in developed versus developing world: an evidence-based review on protease inhibitor use among women and minorities. <i>International Journal of STD and AIDS</i> , 2012, 23, 837-842.	1.1	2
83	Aetiology and outcome of pneumoniae in HIV-positive patients in the antiretroviral era. <i>Infectious Diseases</i> , 2017, 49, 225-228.	2.8	2
84	Migrations do not modify Mycobacterium tuberculosis resistance rates: a 20-year retrospective study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1083-1087.	2.9	2
85	Clinical Validation and Applicability of Different Tipranavir/Ritonavir Genotypic Scores in HIV-1 Protease Inhibitor-Experienced Patients. <i>Current HIV Research</i> , 2009, 7, 425-433.	0.5	1
86	Response to Antiretroviral Treatment After Failure of NNRTI Plus NRTIs-Based Therapy. Data from the ARCA Collaborative Group. <i>Current HIV Research</i> , 2012, 10, 334-340.	0.5	1
87	Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 547-554.	1.6	1
88	Mitral Valve Infective Endocarditis due to Streptococcus pyogenes: A Case Report. <i>Cureus</i> , 2019, 11, e4461.	0.5	1
89	Immunosuppressive Treatment Does Not Prevent Humoral and Cellular Virus-Specific Immunity in Heart or Lung Recipients with SARS-CoV-2 Pneumonia. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, S145.	0.6	0